Mini-reviews
Vol. 2 No. 4 (2023)
Polycythemia vera and management of the thrombotic risk: an update
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 December 2023
2516
Views
409
Downloads
Authors
Polycythemia vera (PV) is a chronic Philadelphia-negative myeloproliferative neoplasm caused by JAK2 mutation and characterized predominantly by the overproduction of red blood cells. The current treatment strategies of PV are based on periodic phlebotomies aimed at preventing thrombotic events associated with increased hematocrit levels. Additional therapies to mitigate the thrombotic burden, which represents the most important predictor of reduced survival in PV patients, include cytoreductive therapies, low-dose aspirin, and systemic anticoagulation. This concise review summarizes the current knowledge on the management of the thrombotic risk in PV patients.
Downloads
Download data is not yet available.
Citations
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2024;98:1465-87. DOI: https://doi.org/10.1002/ajh.27002
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021;35:3339-351. DOI: https://doi.org/10.1038/s41375-021-01401-3
Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020;42:100714. DOI: https://doi.org/10.1016/j.blre.2020.100714
Grunwald MR, Stein BL, Boccia RV, et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:788-95. DOI: https://doi.org/10.1016/j.clml.2018.08.009
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. DOI: https://doi.org/10.1016/j.mayocp.2018.08.022
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019;3:1729-37. DOI: https://doi.org/10.1182/bloodadvances.2019000211
Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol 2017;92:1131-6. DOI: https://doi.org/10.1002/ajh.24851
Landolfi R, Marchioli R, Kutti J, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24. DOI: https://doi.org/10.1056/NEJMoa035572
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224–32. DOI: https://doi.org/10.1200/JCO.2005.07.062
Mainoli B, Duarte GS, Costa J, Ferreira J, Caldeira D. Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2021;21:63-71. DOI: https://doi.org/10.1007/s40256-020-00409-x
How to Cite
1.
Franchini M. Polycythemia vera and management of the thrombotic risk: an update. Bleeding Thromb Vasc Biol [Internet]. 2023 Dec. 20 [cited 2026 Apr. 12];2(4). Available from: https://www.btvb.org/btvb/article/view/102
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo, Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Rossana Cannas, PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026): 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
- CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Tiziano Martini, Alessandra Valpreda, Marina Marchetti, Alberto Catalano, Laura Contino, Raimondo De Cristofaro, Augusto Bramante Federici, Ilaria Quaglia, Rossana Rossi, Rita Carlotta Santoro, Armando Tripodi, Angelo Claudio Molinari, Diagnostic challenges in current laboratory practice at Italian Hemophilia Centers: findings from a nationwide survey , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. 1 (2026)
- PO44 | Emicizumab in acquired haemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Doris Barcellona, Cardiovascular risk in hormone replacement therapy , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. 1 (2026)
- CO15 | Longitudinal coagulation profiling of individuals undergoing gender-affirming hormone therapy: the hyper-gender study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Gary E. Raskob, Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Zara Sayar, PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026): 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
- PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
